Literature DB >> 18072730

Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.

Swati Biswas1, Suhong Zhang, Fernando Fernandez, Balaram Ghosh, Juan Zhen, Eldo Kuzhikandathil, Maarten E A Reith, Aloke K Dutta.   

Abstract

This paper describes an extended structure-activity relationships study of aminotetralin-piperazine-based hybrid molecules developed earlier for dopamine D2/D3 receptors. Various analogues as positional isomers have been developed where location of the phenolic hydroxyl group has been varied on the aromatic ring. Between two catechol derivatives, compound 6e with a two methylene linker length exhibited higher affinity and selectivity for D3 over D2 receptors over compound 6f with four methylene linkers (D2/D3 = 50.6 vs 7.51 for 6e and 6f, respectively). In general, the (-)-isomer was more potent than the (+)-isomeric counterpart. Binding results indicated highest selectivity for D3 receptors in compound (-)- 10 ( K i = 0.35 nM; D2/D3 = 71). In the 5-hydroxy series, highest selectivity for D3 receptors was exhibited by compound (-)- 25 ( K i = 0.82 nM; D2/D3 = 31.5). Most potent compounds exhibited binding and functional affinities at the sub-nanomolar level for the D3 receptor. Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptors by using tritiated spiperone as radioligand for competition studies to evaluate inhibition constants ( K i). A functional assay of selected compounds for stimulating GTPgammaS binding was carried out with CHO cells expressing human D2 receptors and AtT-20 cells expressing human D3 receptors. The functional assay results indicated partial to full agonist characteristics of test compounds. Compound (-)- 25 was selected further for in vivo study to evaluate its potency in producing contralateral rotations in rats with unilateral lesion in the nigrostriatal region induced by neurotoxin 6-OHDA, a Parkinsonian animal model. Compound (-)- 25 at 5 micromol/kg exhibited rotational activity that lasted beyond 12 h, whereas at a 1 micromol/kg dose the rotations lasted beyond 8 h.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18072730     DOI: 10.1021/jm070860r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.

Authors:  Mark Johnson; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2012-06-13       Impact factor: 7.446

2.  N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.

Authors:  Ashwini K Banala; Benjamin A Levy; Sameer S Khatri; Cheryse A Furman; Rebecca A Roof; Yogesh Mishra; Suzy A Griffin; David R Sibley; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2011-05-02       Impact factor: 7.446

3.  Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.

Authors:  Dennis A Brown; Manoj Mishra; Suhong Zhang; Swati Biswas; Ingrid Parrington; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2009-04-19       Impact factor: 3.641

4.  Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.

Authors:  Dennis A Brown; Prashant S Kharkar; Ingrid Parrington; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

5.  Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels.

Authors:  Eldo V Kuzhikandathil; Samantha Cote; Soumava Santra; Aloke K Dutta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-20       Impact factor: 3.000

6.  Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.

Authors:  Sanjib Gogoi; Swati Biswas; Gyan Modi; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Med Chem Lett       Date:  2012-10-26       Impact factor: 4.345

7.  Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.

Authors:  Bhaskar Gopishetty; Suhong Zhang; Prashant S Kharkar; Tamara Antonio; Maarten Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2013-04-01       Impact factor: 3.641

8.  Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.

Authors:  Balaram Ghosh; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

Review 9.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

10.  Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.

Authors:  Gyan Modi; Chandrashekhar Voshavar; Sanjib Gogoi; Mrudang Shah; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Chem Neurosci       Date:  2014-07-09       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.